In this article by Torys LLP, they explain an announcement from Health Canada that makes it easier and faster for new biologic and biosimilar medicines to be approved. The updated rules offer more flexibility, reduce the need for lengthy comparative trials, and simplify the data required for submissions. Together, these changes are designed to cut down on wait times, speed up access to treatments, and support innovation. They show a commitment to ensuring Canadians benefit from the latest therapies as quickly and safely as possible.